Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1.5% – Here’s What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price traded up 1.5% on Wednesday . The company traded as high as $6.88 and last traded at $6.84. 853,370 shares changed hands during trading, a decline of 85% from the average session volume of 5,672,783 shares. The stock had previously closed at $6.74.

Analyst Ratings Changes

RXRX has been the topic of several recent research reports. Jefferies Financial Group decreased their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. KeyCorp decreased their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Finally, Needham & Company LLC dropped their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Price Performance

The stock has a fifty day moving average price of $6.70 and a 200-day moving average price of $7.67. The company has a market cap of $1.90 billion, a PE ratio of -4.21 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. During the same quarter in the prior year, the firm earned ($0.38) earnings per share. The company’s revenue was up 30.9% on a year-over-year basis. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the transaction, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,939,803.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $7.56, for a total value of $45,360.00. Following the transaction, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,939,803.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Gibson sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $7.10, for a total value of $213,000.00. Following the sale, the chief executive officer now directly owns 758,738 shares of the company’s stock, valued at $5,387,039.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 201,682 shares of company stock valued at $1,322,013 in the last three months. Corporate insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RXRX. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals during the third quarter valued at about $25,000. Farther Finance Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the last quarter. GAMMA Investing LLC boosted its stake in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares during the period. Amalgamated Bank grew its holdings in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the last quarter. Finally, San Luis Wealth Advisors LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth approximately $69,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.